Ads
related to: will macrobid treat lactobacillus uti treatmenturosupport.com has been visited by 10K+ users in the past month
reviewscout.org has been visited by 100K+ users in the past month
amazon.com has been visited by 1M+ users in the past month
Search results
Results From The WOW.Com Content Network
Nitrofurantoin, sold under the brand name Macrobid among others, is an antibacterial medication of the nitrofuran class used to treat urinary tract infections (UTIs), although it is not as effective for kidney infections. [16] It is taken by mouth. [16] Common side effects include nausea, loss of appetite, diarrhea, and headaches. [16]
Within the penicillin class, pivmecillinam is considered the first-line empiric treatment for acute cystitis due to its wide spectrum of activity against gram-negative bacteria and its specific efficacy in the urinary tract. It has consistently demonstrated a high cure rate of over 85% for UTIs and a low resistance rate among E. coli strains.
LACTIN-V, also known as CTV-05 or as Lactobacillus crispatus CTV-05, is a live biopharmaceutical medication containing a strain of Lactobacillus crispatus (L. crispatus) which is under development for the treatment of urinary tract infections (UTIs) and bacterial vaginosis (BV).
Urinary tract infections, bacterial prostatitis, community-acquired pneumonia, bacterial diarrhea, mycoplasmal infections, gonorrhea: Nausea (rare), irreversible damage to central nervous system (uncommon), tendinosis (rare) Inhibits the bacterial DNA gyrase or the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription ...
In some men, chronic bacterial prostatitis can be severe and highly refractory to treatment or relapsing. [34] [35] In addition, it can be life-threatening due to urinary tract infections (UTIs). [35] Prostatectomy, or prostate removal surgery, has been used rarely and in well-selected patients to treat these kinds of cases.
The first in a new class of narrow-spectrum macrocyclic antibiotics, fidaxomicin, has been approved for the treatment of C. difficile colitis. [162] New cephalosporin-lactamase inhibitor combinations also approved include ceftazidime-avibactam and ceftolozane-avibactam for complicated urinary tract infection and intra-abdominal infection. [162]